Literature DB >> 21277621

The impact of co-morbid conditions on family history of venous thromboembolism in Whites and Blacks.

Fatima D Mili1, W Craig Hooper, Cathy Lally, Harland Austin.   

Abstract

INTRODUCTION: Our objectives were to compare the magnitude of family history as a risk factor for venous thromboembolism (VTE) risk between Blacks and Whites, and to assess the impact of co-morbid conditions on familial risk for VTE.
MATERIALS AND METHODS: We used data from the Genetic Attributes Thrombosis Epidemiology (GATE) study, a matched case-control study which enrolled Blacks and Whites aged 18-70years in Atlanta, Georgia. A total of 1,094 case patients with a deep vein thrombosis (DVT) or pulmonary embolism (PE) and 1,264 control patients were interviewed about their family history.
RESULTS: Family history of VTE was a statistically significant risk factor for VTE among Blacks (odds ratio (OR)=2.9, 95% confidence interval (CI) 2.0-4.1; P value<0.0001) and among Whites (OR=2.7, 95% CI 1.9-3.7; P value<0.0001); among Blacks and Whites who were obese or had hypertension; among Blacks who had diabetes mellitus or cancer; as well as among males and females, and across all age categories. Family history of VTE increased the risk of VTE among Blacks with cancer by about 6-fold, whereas among Blacks without cancer the increased risk due to a positive family history was about 3-fold; a 2-fold relative difference. In addition, family history was a risk factor for VTE among case patients with DVT only or with PE only. The effect of family history generally was stronger among those with recurrent episodes of VTE compared with a first episode of VTE. For example, family history of any VTE was a strong risk factor among Black females with recurrent VTE compared with Black females with first VTE (OR=3.9, 95% CI 2.0-7.5; P value<0.0001).
CONCLUSION: Our study indicated that the adjusted attributable fraction for VTE was 16.9% among Blacks vs. 18.3% among Whites, and certain co-morbid conditions could further increase the risk of VTE associated with a positive family history of VTE. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21277621     DOI: 10.1016/j.thromres.2010.12.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Comparison of prospective risk estimates for postoperative complications: human vs computer model.

Authors:  Robert E Glasgow; Mary T Hawn; Patrick W Hosokawa; William G Henderson; Sung-Joon Min; Joshua S Richman; Majed G Tomeh; Darrell Campbell; Leigh A Neumayer
Journal:  J Am Coll Surg       Date:  2013-11-13       Impact factor: 6.113

2.  Family history of myocardial infarction is a risk factor for venous thromboembolism among whites but not among blacks.

Authors:  Fatima D Mili; W Craig Hooper; Cathy Lally; Harland Austin
Journal:  Clin Appl Thromb Hemost       Date:  2012-06-12       Impact factor: 2.389

3.  The effects of obesity on venous thromboembolism: A review.

Authors:  Genyan Yang; Christine De Staercke; W Craig Hooper
Journal:  Open J Prev Med       Date:  2012-11

4.  Increased risk of venous thromboembolism is associated with genetic variation in heme oxygenase-1 in Blacks.

Authors:  Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Heidi Trau; Nafisa Ghaji; W Craig Hooper; Harland Austin
Journal:  Thromb Res       Date:  2012-09-07       Impact factor: 3.944

5.  Familial Clustering of Venous Thromboembolism - A Danish Nationwide Cohort Study.

Authors:  Caroline Sindet-Pedersen; Louise Bruun Oestergaard; Anna Gundlund; Emil Loldrup Fosbøl; Kristian Aasbjerg; Jannik Langtved Pallisgaard; Gunnar Gislason; Christian Torp-Pedersen; Jonas Bjerring Olesen
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

6.  Association of SERPINC1 Gene Polymorphism (rs2227589) With Pulmonary Embolism Risk in a Chinese Population.

Authors:  Yongjian Yue; Qing Sun; Lu Xiao; Shengguo Liu; Qijun Huang; Minlian Wang; Mei Huo; Mo Yang; Yingyun Fu
Journal:  Front Genet       Date:  2019-09-13       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.